Abstract: This invention relates to a surface coating for capture circulating rare cells, comprising a nonfouling composition to prevent the binding of non-specific cells and adsorption of serum components; a bioactive composition for binding the biological substance, such as circulating tumor cells; with or without a linker composition that binds the nonfouling and bioactive compositions. The invention also provide a surface coating for capture and purification of a biological substance, comprising a releasable composition to release the non-specific cells and other serum components; a bioactive composition for binding the biological substance, such as circulating tumor cells; with or without a linker composition that binds the releasable and bioactive compositions. The present invention also discloses a novel microfluidic chip, with specific patterned microstructures to create a flow disturbance and increase the capture rate of the biological substance.
Abstract: Disclosed herein are recombinant antibodies or the fragment thereof for detecting severe acute respiratory syndrome coronavirus (SARS-CoV). According to some embodiments, the SARS-CoV is SARS-CoV-1. According to some alternative embodiments, the SARS-CoV is SARS-CoV-2. Also disclosed herein are a kit comprising the recombinant antibodies, and a method for diagnosing the infection of SARS-CoV by using the recombinant antibody or the kit.
Abstract: Disclosed herein are recombinant viruses and/or insect cells suitable for detecting the infection of a pathogen in a biological sample of a test subject. The information derived from the detection may also be used to render a diagnosis on whether the test subject is infected with the pathogen or not, so that proper course of treatment may be assigned to the subject. Also disclosed herein is a vaccine for the prophylaxis and/or treatment of infection caused by said pathogen.
Abstract: The present invention provides a gene delivery vehicle comprising a heterologous genome capable of upregulating the expression of HMGCS2 in human heart and, in particular, in the cardiomyocyte (CM). Upregulating the expression of HMBCS2 causes a metabolic switch that facilitates CM dedifferentiation and regeneration under myocardial infarction or hypoxic conditions. The present invention also provides a method of therapy for protection and/or regeneration of the human heart and, in particular, in the CM by administration of the composition of the present invention to the patient.
Type:
Application
Filed:
October 7, 2022
Publication date:
May 18, 2023
Applicant:
Academia Sinica
Inventors:
Patrick Ching-Ho Hsieh, Yuan-Yuan Cheng
Abstract: A fusion protein including a phage tail-spike protein ?AB6TSP and a signal indicator is provided. Also, a method of detecting bacteria having pseudaminic acid (Pse) is provided, including steps of contacting a sample with a phage tail-spike protein ?DAB6TSP; and detecting a signal from the sample. The fusion protein and the method of detecting bacteria can be applied to a set of practical diagnosis and therapeutic alternative against Pse-coated antibiotic resistant pathogenic bacteria.
Abstract: Compounds of Formula (I) and methods for treating, delaying, and/or preventing the adverse effects of proliferative diseases, such as cancers including, for example, lung cancer, breast cancer, ovarian cancer, prostate cancer, head cancer, neck cancer, head and neck cancer, or leukemia (e.g., cancer resistant to treatment by one or more microtubule-targeting agents, e.g., cancer resistant to multiple drugs associated with P-glycoprotein (P-gp) overexpression). Methods of inhibiting polymerization of a cancer cell microtubule in a subject in need thereof or a cell, tissue, or biological sample, binding ?-tubulin, inhibiting microtubule assembly and, inducing apoptosis in a cancer cell resistant to multiple drugs in a tissue, biological sample, or subject. Pharmaceutical compositions, kits, and methods of using the compounds for treating any of the target diseases described herein.
Abstract: A method of inhibiting an overactive fibroblast growth factor receptor 3 (FGFR3) in a cell by contacting the cell with a composition that contains an effective amount of Pheophorbide a, Pyropheophorbide a, or an active derivative thereof. Also disclosed is a method for treating a disorder associated with an overactive FGFR3 with a composition containing an effective amount of Pheophorbide a, Pyropheophorbide a, or an active derivative thereof. Further, a composition for treating a disorder associated with an overactive FGFR3 is described. The composition contains an ethanol extract of Amaranthus viridis.
Type:
Grant
Filed:
February 8, 2018
Date of Patent:
April 18, 2023
Assignee:
ACADEMIA SINICA
Inventors:
Yuan-Tsong Chen, Yi-Ching Lee, Jer-Yuam Wu, Hsiao-Jung Kao
Abstract: A method of expanding natural killer cells, comprising: providing a population of internally gelated cells, each of which includes a gelated interior and a fluid cell membrane that contains one or more membrane-bound proteins each or collectively are capable of stimulating expansion of natural killer (NK) cells; and culturing a population of cells containing NK cells, which are capable of responding to the one or more membrane-bound proteins, with the population of internally gelated cells under conditions that allow expansion of NK cells.
Abstract: Disclosed herein are novel methods for hydrolyzing eggshell membrane (ESM). In one embodiment, the method includes cultivating thermophilic bacteria in a solution containing 1-10% (wt %) ESM to decompose the ESM into the ESM hydrolysate; wherein, the thermophilic bacteria grow on the ESM as their sole source of nutrient. In another embodiment, the method includes treating ESM with a keratinase in the presence of a reducing agent at a condition sufficient to produce the ESM hydrolysate, in which the keratinase, the reducing agent, and the ESM are present in a weight ratio of 1:120:600. The thus produced ESM hydrolysate is enriched in essential amino acids, collagen, peptides and glycosaminoglycans.
Type:
Application
Filed:
September 29, 2022
Publication date:
March 30, 2023
Applicants:
Academia Sinica, I-MEI FOODS CO., LTD.
Inventors:
Shih-Hsiung WU, Ya-Chu LIEN, Chi-Ming KAO, Ken-Pei WONG
Abstract: The present invention is directed to genetically-modified non-human animal models with specific mutations in exon 3 of proline-rich acidic protein 1 (PRAP1) gene. Also disclosed herein are methods of treating hyperlipidemia or a hyperlipidemia-related disease by using a PRAP1 inhibitor or a modified PRAP1 polypeptide, as well as pharmaceutical compositions comprising the modified PRAP1 polypeptide.
Abstract: The present invention relates to a recombinant poxviral vector for use in vaccinating a subject against SARS-CoV-2. The present invention also provides vaccination regimens using the recombinant poxviral vector, which confers protective immunity against SARS-CoV-2.
Type:
Application
Filed:
July 21, 2022
Publication date:
March 2, 2023
Applicant:
ACADEMIA SINICA
Inventors:
Wen Chang, Rakesh Kulkarni, Shiu-Lok Hu
Abstract: The invention relates to a genetically modified mouse comprising a heterozygous mutation of Tardbp (TDP-43) gene in that the Asn at amino acid 390 in TDP-43 is substituted with an amino acid that is different from Asn, wherein the genetically modified mouse exhibits Amyotrophic lateral sclerosis (ALS)-like phenotypes, TDP-43 proteinopathies and/or motor neuron degeneration. The invention also so relates to an isolated spinal cord motor neuron differentiated from an embryonic stem cell (ESC) that is obtained from an offspring of a genetically modified mouse according to the invention. Methods for identifying an agent alleviating and/or suppressing ALS-TDP pathogenesis are also disclosed.
Abstract: Disclosed herein is a recombinant antibody exhibiting binding affinity and/or neutralizing activity to porcine epidemic diarrhea virus (PEDV). According to some embodiments of the present disclosure, the PEDV is genotype 1 (G1) or genotype 2b (G2b) PEDV. Also disclosed herein are methods of diagnosing and treating PEDV infection by use of the present recombinant antibody.
Type:
Application
Filed:
June 28, 2022
Publication date:
February 9, 2023
Applicant:
Academia Sinica
Inventors:
Shang-Te Danny HSU, Hui-Wen CHANG, Chia-Yu CHANG
Abstract: The present disclosure provides a substrate for cell culture. Systems comprising the substrate, and methods for using and manufacturing the substrate are also disclosed herein.
Abstract: A natural language processing method, comprising: receiving multiple input words; and reducing the multiple words into one or more subject word data structures according to sets stored in a database, wherein one of the subject word data structures includes a first input word and a second input words among the input words, wherein one of the sets includes a compatible relation between the first input word and the second input word, wherein the compatible relation between the first input word and the second word includes a compatible property for denoting an intensity representing occurrences of the first input word and the second word in a training corpus.
Abstract: Disclosed herein is a device for synthesizing ribonucleic acids (RNAs). According to embodiments of the present disclosure, the device comprises an in vitro transcription (IVT) module, a digestion module, and a processor. Optionally, the present device further comprises an IVT reaction monitoring means, a digestion reaction monitoring means, and/or a purifying means. Also disclosed herein are the methods of synthesizing RNA by use of the present device.
Abstract: The present disclosure provides a method for detecting cholangiocarcinoma cells. The capture rate of the cholangiocarcinoma cells of the present disclosure is higher than 70%, and a plurality of octasaccharides with high affinity and specificity can be modified on the surface of magnetic beads to capture and analyze cholangiocarcinoma cells under test, wherein the cholangiocarcinoma cells can be circulating tumor cells in cholangiocarcinoma.
Type:
Grant
Filed:
July 19, 2019
Date of Patent:
January 10, 2023
Assignees:
NATIONAL TSING HUA UNIVERSITY, ACADEMIA SINICA
Inventors:
Gwo Bin Lee, Shang-Cheng Hung, Wei-Chun Tsai
Abstract: Provided herein is a method for improving growth, stress tolerance and productivity of a plant. Also provided herein is a method for increasing seed quality of a plant. Specifically, the disclosure provides a method for improving growth, stress tolerance and productivity of a plant, comprising: providing a transgenic plant, which includes a reduced expression on an MYBS2 gene as relative to its wild-type counterpart; and a method for increasing seed quality of a plant, comprising: providing a seed from a transgenic plant, which overexpresses a full-length MYBS2 gene or a mutant MYBS2 gene as relative to its wild-type counterpart.
Type:
Application
Filed:
September 17, 2020
Publication date:
January 5, 2023
Applicants:
ACADEMIA SINICA, NATIONAL CENTRAL UNIVERSITY
Inventors:
Su-May YU, Yi-Shih CHEN, Chung-An LU, Tuan-Hua David HO
Abstract: Disclosed herein is a biomolecule comprising a synthetic peptide for targeting thrombus, a pharmaceutical composition comprising the same, and uses thereof in the treatment of thromboembolism-related diseases. According to embodiments of the present disclosure, the synthetic peptide having the amino acid sequence of SEQ ID NO: 1, 2, or 3 exhibits a binding affinity and specificity to thrombus. Thus, the synthetic peptide may serve as a targeting element for delivering a therapeutic agent (e.g., an anticoagulant agent or a thrombolytic agent) to the thrombus thereby improving the therapeutic safety and efficacy of the therapeutic agent.